Assessment Of The Rational Use Of Anti Diabetics In Type 2 Diabetes Mellitus Using Case Notes Of Patients At A Tertiary Health Care Centre In South West Nigeria
Keywords:
Patients, Type 2 Diabetes Mellitus, Endocrinology, Antidiabetics
Abstract
This study was a prospective study of cases at the University College Hospital, Ibadan. A total of four in-patients comprising of two male and two female adults of the Endocrinology unit were monitored for the study. Patients#x2019; case notes and drug administration charts were used to obtain necessary drug information in addition to information obtained directly from the patients. The age group distribution of the patients was found to be between 34-64 years. The mean age was 47.5 years. The drug regimen showed that Patients A, B, C and D received a total of 8, 10, 11 and 7 drugs respectively. These included Metformin, Insulin, Glibenclamide and Glimepiride as antidiabetic agents. Other drugs prescribed for coexisting diseases included: Nifedipine, Lisinopril, Alpha-methyldopa and Hydrochlorothiazide as Antihypertensives, Atorvastatin as Lipid-Lowering agents and Ceftriaxone, Lxime, Metronidazole, Ciprofloxacin as Antibiotics. Analgesics such as paracetamol and Hematinics such as ferrous sulphate were also prescribed as needed. Co-morbidities studied include hyperglycemic coma, peripheral neuropathy, Diabetic foot disease, Diabetic ketoacidosis, Hypertension and Hyperlipidemia. The results were documented and analysed using charts and tables.
Downloads
- Article PDF
- TEI XML Kaleidoscope (download in zip)* (Beta by AI)
- Lens* NISO JATS XML (Beta by AI)
- HTML Kaleidoscope* (Beta by AI)
- DBK XML Kaleidoscope (download in zip)* (Beta by AI)
- LaTeX pdf Kaleidoscope* (Beta by AI)
- EPUB Kaleidoscope* (Beta by AI)
- MD Kaleidoscope* (Beta by AI)
- FO Kaleidoscope* (Beta by AI)
- BIB Kaleidoscope* (Beta by AI)
- LaTeX Kaleidoscope* (Beta by AI)
How to Cite
Published
2012-03-15
Issue
Section
License
Copyright (c) 2012 Authors and Global Journals Private Limited
This work is licensed under a Creative Commons Attribution 4.0 International License.